Morales-Garcia JA, Luna-Medina R, Alonso-Gil S, Sanz-Sancristobal M, Palomo V, Gil C, Santos A, Martinez A, Perez-Castillo A.
Source : Instituto de Investigaciones Biomédicas , (CSIC-UAM), Arturo Duperier, 4 and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28029-Madrid, Spain.
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase originally identified as a regulator of glycogen metabolism but it also plays a pivotal role in numerous cellular functions, including differentiation, cell cycle regulation, and proliferation. The dentate gyrus of the hippocampus, together with the subventricular zone of the lateral ventricles, is one of the regions in which neurogenesis takes place in the adult brain. Here, using a chemical genetic approach that involves the use of several diverse inhibitors of GSK-3 as pharmacological tools, we show that inhibition of GSK-3 induces proliferation, migration, and differentiation of neural stem cells toward a neuronal phenotype in in vitro studies. Also, we demonstrate that inhibition of GSK-3 with the small molecule NP03112, called tideglusib, induces neurogenesis in the dentate gyrus of the hippocampus of adult rats. Taken together, our results suggest that GSK-3 should be considered as a new target molecule for modulating the production and integration of new neurons in the hippocampus as a treatment for neurodegenerative diseases or brain injury and, consequently, its inhibitors may represent new potential therapeutic drugs in neuroregenerative medicine.
LURBINECTEDIN EEUU : LAS VENTAS EN EL 1er SEMESTRE 25 HAN SIDO DE 137,5 MILL$ // SE HAN REDUCIDO UN 12% QUE SON 18,6 MILL$ MENOS Vs A LAS ALCANZADAS EN EL MISMO PERIODO DE 2024 QUE FUERON DE 156,1 MILL$ // VENTAS DE TARLATAMAB EN.EL 2o TRIM 25 HAN ALCANZADO LOS 134 MILL$ ... UN 65% MÁS ... VERSUS LOS 61 MILL$ QUE ALCANZÓ EN EL 1er TRIM25 // TARLA 1er SEMESTRE 25 = VENTAS DE 215 MILL$ ... QUE SON 77,8 MILL$ MÁS QUE LOS ALCANZADOS POR LURBI (137,5 MILL$) EN EL MISMO PERIODO
25 noviembre 2012
El sistema robótico Da Vinci permite realizar intervenciones Oncologicas complejas con la mínima invasión .
Se emplea en todos los tumores situados en órganos de la cavidad abdominal y facilita un post operatorio más rápido y un menor impacto psicológico sobre el paciente .
...
...
Suscribirse a:
Entradas (Atom)